<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="179820">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753935</url>
  </required_header>
  <id_info>
    <org_study_id>040065</org_study_id>
    <secondary_id>5P50HL081009-03</secondary_id>
    <nct_id>NCT00753935</nct_id>
  </id_info>
  <brief_title>Aspirin Resistance in Coronary Artery Disease</brief_title>
  <official_title>Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a
      molecular level in aspirin-treated patients with coronary artery disease. We hypothesize
      that certain patient characteristics associate with aspirin resistance. In addition, we will
      compare the effects of enteric-coated aspirin and chewable aspirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aspirin is commonly used for its antithrombotic effects in patients at risk for
      cardiovascular events. Its primary mechanism of action is the irreversible acetylation of
      platelet cyclooxygenase-1, thereby inhibiting platelet production of thromboxane A2, a
      potent vasoconstrictor and activator of platelets. Previous studies have demonstrated that
      many patients have recurrent events despite treatment with aspirin, which has been termed
      &quot;aspirin resistance&quot; or &quot;aspirin nonresponse.&quot; This study addresses some of the possible
      mechanisms for aspirin nonresponse; specifically, we will test the hypothesis that aspirin
      nonresponse results from states that produce high peroxide concentrations (&quot;oxidative
      stress&quot;) in platelets. In addition, we will evaluate the effect of enteric coating on the
      pharmacologic efficacy of aspirin in patients with coronary artery disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single Blind (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum thromboxane B2</measure>
    <time_frame>after 2 weeks of aspirin</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>enteric-coated aspirin 81mg daily for 2 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>acetylsalycylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>chewable aspirin 81mg daily for 2 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>acetylsalycylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On aspirin 81-325mg daily at time of enrollment

          -  Documented stable coronary artery disease or &gt; 6 months after CABG or interventional
             cardiac procedure

          -  Written informed consent

        Exclusion Criteria:

          -  Pre-menopausal female

          -  Renal disease (creatinine &gt;= 2 mg/dl)

          -  Anemia (Hematocrit &lt; 30%)

          -  Thrombocytopenia (platelet count &lt; 135,000/ul)

          -  Use of NSAIDs or coxibs within the previous 2 weeks

          -  Concurrent use of other anti-platelet agents

          -  Uncontrolled hypertension (systolic BP &gt; 180 mmHg)

          -  Decompensated congestive heart failure

          -  Recent coronary syndrome (&lt; 6 months)

          -  History of significant GI bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary B Taylor, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 12, 2010</lastchanged_date>
  <firstreceived_date>September 15, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Mary B. Taylor, MD</name_title>
    <organization>Vanderbilt University Medical Center</organization>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>aspirin resistance</keyword>
  <keyword>aspirin nonresponse</keyword>
  <keyword>cyclooxygenase</keyword>
  <keyword>thromboxane</keyword>
  <keyword>oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
